Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Back

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Recruiting

Open to: ALL

Age: 18.0 - N/A

Bristol London Salford Swansea Dundee Canterbury Glasgow London Cardiff Southampton Bradford Hounslow

Medical Conditions

Chronic Kidney Disease and Hypertension

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2025 Dec 2029

Publications

"Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026 Feb 1;37(2):299-311. doi: 10.1681/ASN.0000000849. Epub 2025 Sep 6."; "40913594"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : baxdrostat tablet

dapagliflozin tablet

Intervention Arm Group : Baxdrostat/dapagliflozin;

Intervention Type : DRUG
Intervention Description : dapagliflozin tablet

placebo tablet

Intervention Arm Group : Placebo/dapagliflozin;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Bristol
    BS105NB
  • Research Site
    London
    E1 1BB
  • Research Site
    Salford
    M6 8HD
  • Research Site
    Swansea
    SN6 6NL
  • Research Site
    Dundee
    DD1 9SY
  • Research Site
    Canterbury
    CT1 3NG
  • Research Site
    Glasgow
    G51 4TF
  • Research Site
    London
    SE5 9RS
  • Research Site
    Cardiff
    CF14 4XW
  • Research Site
    Southampton
    SO16 6YD
  • Research Site
    Bradford
    BND9 6RJ
  • Research Site
    Hounslow
    TW3 3LN

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06742723
Last updated 25 March 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top